Clinical Trials Logo

Filter by:
NCT ID: NCT00824655 Completed - Clinical trials for Pneumococcal Vaccines

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purposes of this study are to evaluate the safety of 13-valent pneumococcal Conjugate Vaccine (13vPnC) in children who have already been vaccinated with Prevenar. The study will also assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine at 5 and 12 months or 12 months of age. In addition, reactions at the injection site will be assessed during the study.

NCT ID: NCT00821912 Active, not recruiting - Clinical trials for Cancer of the Esophagus

TaxXel: Taxotere and Xeloda in Esophageal Cancer

TaxXel
Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, non-randomised, multicentre phase 1-2 study with a fixed dose of Taxotere in combination with Xeloda which is dose escalated during the first phase of the study (modified Fibonacci design) and fixed during the second phase. The primary objective of the phase 1 part is to define the dose recommended for the Phase II part of the study. The primary objective is to determine the response rate.

NCT ID: NCT00820222 Completed - Metastases, Brain Clinical Trials

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Start date: April 14, 2009
Phase: Phase 3
Study type: Interventional

This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.

NCT ID: NCT00819351 Completed - Clinical trials for Acute Lymphoblastic Leukemia

ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase

Start date: January 1, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of Event Free Survival

NCT ID: NCT00818623 Completed - Prostate Cancer Clinical Trials

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this trial was to find an optimal dose for a new trial drug - degarelix (FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was studied. Patients participating were treated with FE200486 on one occasion. Thereafter they came in for visits following a specific schedule until blood samples showed that there was no further effect.

NCT ID: NCT00816244 Completed - Breast Cancer Clinical Trials

Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer

Start date: January 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to monitor: - Tumor biological alterations following two weeks of neo-adjuvant statin therapy. - Effects of statins on tumor proliferation. - Functional studies on the mevalonate pathway.

NCT ID: NCT00816049 Completed - Clinical trials for Acute Lymphoblastic Leukemia

ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy

ALL2008con
Start date: January 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to increase the fraction of patients, who become MRD-negative during consolidation for the non-HR ALL group through individualized intensification of the 6MP-dosage days 30-85.

NCT ID: NCT00814489 Completed - Clinical trials for Streptococcus Pneumoniae

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

Start date: January 8, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of a non-typable Haemophilus influenzae and pneumococcal candidate vaccine in young adults. Subjects will be vaccinated 2 times in an observer-blind manner with an interval of 2 months. The subjects receiving Engerix-B will receive in an open-manner a third dose of the vaccine at Month 6. The protocol posting has been updated following a protocol amendment.

NCT ID: NCT00814112 Withdrawn - Septic Shock Clinical Trials

Glycosaminoglycans During Septic Shock - a Temporal Study

GAGS
Start date: November 2008
Phase:
Study type: Observational

We have previously shown that the plasma level of glycosaminoglycans (GAG) in septic shock patients are elevated compared to controls. The purpose of this study is to investigate the temporal dynamic of the blood level of GAG in ten septic shock patients. In addition, to assess the kinetics of GAG during septic shock we examine the liver function by galactose elimination capacity as well as excreted urinary GAG.

NCT ID: NCT00812643 Completed - Healthy Clinical Trials

Excretion of Radiolabelled AZD0837

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This is an explorative study and the scientific question to be investigated in this study is if AZD0837 and/or its metabolites AR-H069927XX and AR-H067637XX and other unknown metabolites are excreted into the bile.